Investigational drug · Phase 2
FPI-2265
Also called: AZD2265, 225Ac-PSMA-I&T, Ac225-PSMA I&T
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Metastatic Castration Resistant Prostate Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
5
Any phase or sponsor naming "FPI-2265"
First trial start
2021
Dec 16, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "FPI-2265", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Castration-resistant Prostate Cancer
- Metastatic Prostate Cancer
- Metastatic Castration Resistant Prostate Cancer
Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "FPI-2265" as an intervention, largest first.
- AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07611110 · 670 participants (planned) · Start May 4, 2026 · Primary completion Jun 4, 2029
Drug: Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]); Cabazitaxel and 6 more · For: Metastatic Castration-resistant Prostate Cancer
Sites: Dothan, Alabama; Phoenix, Arizona; Duarte, California · 151 sites in all
- Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate CancerPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07590934 · 152 participants (planned) · Start Jun 3, 2026 · Primary completion Sep 25, 2029
Drug: AZD2265 (FPI-2265); Palacaparib (AZD9574) and 2 more · For: Metastatic Prostate Cancer
Sites: Duarte, California; Encino, California; South Pasadena, California · 38 sites in all
- Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).Active, not recruiting
Fusion Pharmaceuticals Inc.Industry
NCT05219500 · 115 participants (planned) · Start Dec 16, 2021 · Primary completion May 30, 2025
Drug: FPI-2265 · For: Metastatic Castration Resistant Prostate Cancer
Sites: Omaha, Nebraska; Houston, Texas
- FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)Pivotal-lookingActive, not recruiting
Fusion Pharmaceuticals Inc.Industry
NCT06402331 · 110 participants · Start Mar 5, 2024 · Primary completion Dec 23, 2026
Drug: FPI-2265 · For: Metastatic Castration-resistant Prostate Cancer
Sites: Duarte, California; Irvine, California; Los Angeles, California · 18 sites in all
- FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)Active, not recruiting
Fusion Pharmaceuticals Inc.Industry
NCT06909825 · 85 participants (planned) · Start Feb 26, 2025 · Primary completion May 2027
Drug: FPI-2265; Olaparib · For: Metastatic Castration-resistant Prostate Cancer
Sites: Macquarie Park, Australia; Woolloongabba, Australia; Kurralta Park, Australia · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Metastatic Castration-resistant Prostate Cancer
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- OpevesostatMK-5684, ODM-208Phase 37 trials
Merck & Co. · Prostate Cancer Metastatic, Malignant Neoplasm, Metastatic Castration-resistant Prostate Cancer (mCRPC)
- ONC-392Gotistobart, BNT316Phase 35 trials
OncoC4, Inc. · Non Small Cell Lung Cancer, Ovarian Cancer, Advanced Solid Tumor
- DB-1311BNT324Phase 34 trials
BioNTech SE · Metastatic Castration-resistant Prostate Cancer, Advanced Lung Cancer, Solid Tumors
- MevrometostatPF-06821497Phase 33 trials
Pfizer · Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer
- 177Lu-NYM032Phase 32 trials
Norroy Bioscience Co., LTD · Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
- XaluritamigAMG 509Phase 32 trials
Amgen · Metastatic Castration-resistant Prostate Cancer
- BMS-986365Phase 31 trial
Bristol Myers Squibb · Metastatic Castration-resistant Prostate Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.